Loading...
AbCellera Q1 2025 Earnings Report
AbCellera reported its Q1 2025 business results, with total revenue of $4.2 million and a net loss of $45.6 million.
Key Takeaways
AbCellera reported a total revenue of $4.2 million for Q1 2025, a decrease from $10.0 million in Q1 2024. The company experienced a net loss of $45.6 million, compared to a net loss of $40.6 million in the prior year. Despite the loss, AbCellera maintained strong liquidity with over $800 million in available funds and is advancing new antibody programs into clinical trials.
Total revenue for Q1 2025 was $4.2 million, primarily from research fees.
Net loss for Q1 2025 was $45.6 million, or $(0.15) per share.
The company ended the quarter with over $800 million in available liquidity.
AbCellera plans to start Phase 1 clinical trials for ABCL635 and ABCL575 in the second half of 2025.
Revenue by Segment
Forward Guidance
AbCellera anticipates starting Phase 1 clinical trials for ABCL635 and ABCL575 in the second half of 2025, leveraging its strong liquidity to execute its strategy.
Positive Outlook
- Introduction of ABCL635 as a potential first-in-class antibody for vasomotor symptoms.
- ABCL635 is positioned as a next-generation NK3R antagonist with improved safety and convenient dosing.
- Potential for ABCL635 to be a highly differentiated product in a large market.
- Anticipated start of Phase 1 clinical trials for ABCL635 and ABCL575 in H2 2025.
- Strong available liquidity of over $800 million to execute strategy.
Challenges Ahead
- No specific negative forward guidance was provided in the report.
- The report does not specify any anticipated challenges or risks for the upcoming periods.
- No explicit warnings about potential revenue declines or increased losses were given.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...